Table 2.
Use of pirfenidone and associated side effects in subgroups of patients by weight loss.
| Total | Group with significant weight loss | Group without significant weight loss | P value | |
|---|---|---|---|---|
| Patients, n | 118 | 37 | 81 | |
| Pirfenidone full dose | 53 (44.9) | 15 (40.5) | 38 (46.9) | 0.518 |
| Pirfenidone reduced dose | 65 (55.1) | 22 (59.5) | 43 (53.1) | |
| Duration of pirfenidone therapy (months) | 17.6 ± 9.4 | 16.1 ± 9.8 | 18.2 ± 9.1 | 0.257 |
| Diagnosis to pirfenidone therapy (months) | 2.1 (0.3–6.6) | 2.0 (0.2–4.1) | 2.2 (0.4–7.7) | 0.213 |
| Discontinuation of treatment | 18 (15.3) | 5 (13.5) | 13 (16.0) | 0.722 |
| Side effect | ||||
| GI | 44 (37.3) | 14 (37.8) | 30 (37.0) | > 0.999 |
| Skin | 44 (37.3) | 13 (35.1) | 31 (38.3) | 0.744 |
| GI and skin | 15 (12.7) | 4 (10.8) | 11 (13.6) | 0.774 |
Data presented as mean ± standard deviation, n (%), median (interquartile range).
GI gastrointestinal.